C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD


  • F. Pache
  • M. Ringelstein
  • O. Aktas
  • I. Kleiter
  • S. Jarius
  • N. Siebert
  • J. Bellmann-Strobl
  • F. Paul
  • K. Ruprecht


  • Journal of Neuroimmunology


  • J Neuroimmunol 360: 577699


  • While complement-dependent cytotoxicity (CDC) is a known effector mechanism in aquaporin-4-immunoglobulin (Ig)G-positive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD), the role of CDC in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is less clear. We determined complement C3 and C4 plasma concentrations in patients with clinically stable AQP4-IgG+ NMOSD (n = 16), MOGAD (n = 15), early multiple sclerosis (MS, n = 19) and in healthy controls (HC, n = 18). C4 was lower in AQP4-IgG+ NMOSD than in MOGAD, MS and HC (p < 0.05, pairwise comparisons). C3 was lower in AQP4-IgG+ NMOSD than in MS (p = 0.034). These findings suggest subtle complement consumption in clinically stable AQP4-IgG+ NMOSD, but not in MOGAD.